CLINICAL_TRIALS
trial_result
· 2026-02-27
Clinical Trial Update: MBG453 in Lower Risk MDS [Phase 2]
Summary
A Phase 2 trial of MBG453 for lower-risk myelodysplastic syndromes has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2026-02-27